CA Patent

CA3008312A1 — Novel fluorinated quinazoline derivatives as egfr inhibitors

Assigned to Trillium Therapeutics ULC · Expires 2017-07-13 · 9y expired

What this patent protects

A novel class of fluorinated derivatives of Formula (I) have been prepared and found to be useful in the treatment of cancers and other EGFR related disorders. (I)

USPTO Abstract

A novel class of fluorinated derivatives of Formula (I) have been prepared and found to be useful in the treatment of cancers and other EGFR related disorders. (I)

Drugs covered by this patent

Patent Metadata

Patent number
CA3008312A1
Jurisdiction
CA
Classification
—
Expires
2017-07-13
Drug substance claim
No
Drug product claim
No
Assignee
Trillium Therapeutics ULC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.